BioCentury
ARTICLE | Company News

Achillion rises on positive opinion for C3G therapy

February 26, 2018 9:23 PM UTC

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday.

ACH-4471 is a complement factor D (CFD; adipsin) inhibitor. In November, Achillion reported preliminary data from the first two patients in a Phase IIa trial to treat C3 glomerulopathy showing that the candidate reduced albumin-to-creatinine ratio from baseline to day 17 by 56% in the first patient and by 55% in the second patient...